There have been various studies conducted so far in order to calculate the effects of a multifactorial intervention on the onset and progression of diabetic kidney disease especially in the patients who have been treated with type 2 diabetes. Icosapent ethyl, a highly purified acid, plays a very pivotal role in controlling the infections of the person in the best possible manner. The EVAPORATE trial sought to determine whether IPE 4g/ day, as an adjunct to diet and statin therapy, would result in a greater change from baseline in plaque volume. This has to be measured with the help of multidetector tomography. Therefore, for the purpose of this study, a total of 80 patients were taken so far. These people were the ones who were already infected by the diseases in the best possible manner. The results concluded that the icosapent ethyl demonstrated significant regression of LAP volume on MDCT compared with the placebo over the 18 months and was able to yield positive results in the best possible manner. There have been results that we’re able to showcase that following this therapy with this drug was able to control blood pressure of 54 percent of the people who have been included in the sample of the population.
Ref art: https://www.kidney-international.org/article/S0085-2538(20)30974-1/fulltext